Tower Research Capital (TRC)’s Contineum Therapeutics CTNM Stock Holding History
Bought
Maintained
Sold
Other funds holding CTNM
Tower Research Capital (TRC)'s CTNM Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Contineum Therapeutics (CTNM) stake by 76% in Q3 2026, buying an estimated $24.5K and bringing the position to 3,806 shares worth $51.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3218.
Tower Research Capital (TRC) first reported a position in CTNM in Q2 2024 and has held it in 10 quarters since. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.
- Tower Research Capital (TRC) held 3,806 shares of Contineum Therapeutics worth $51.1K as of Q3 2026.
- Tower Research Capital (TRC) bought 1,642 Contineum Therapeutics shares in Q3 2026, an estimated $24.5K.
- Contineum Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3218 holding.
- Tower Research Capital (TRC) first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 10 quarters since.
- 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.